2-47416318-G-A

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_000251.3(MSH2):​c.965G>A​(p.Gly322Asp) variant causes a missense change. The variant allele was found at a frequency of 0.0145 in 1,612,018 control chromosomes in the GnomAD database, including 240 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).

Frequency

Genomes: 𝑓 0.012 ( 22 hom., cov: 32)
Exomes 𝑓: 0.015 ( 218 hom. )

Consequence

MSH2
NM_000251.3 missense

Scores

1
10
7

Clinical Significance

Benign reviewed by expert panel B:30O:1

Conservation

PhyloP100: 4.65
Variant links:
Genes affected
MSH2 (HGNC:7325): (mutS homolog 2) This locus is frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences (RER+ phenotype) found in HNPCC. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.009123743).
BP6
Variant 2-47416318-G-A is Benign according to our data. Variant chr2-47416318-G-A is described in ClinVar as [Benign]. Clinvar id is 1762.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47416318-G-A is described in Lovd as [Benign]. Variant chr2-47416318-G-A is described in Lovd as [Likely_benign]. Variant chr2-47416318-G-A is described in Lovd as [Likely_pathogenic].
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.0124 (1885/152188) while in subpopulation NFE AF= 0.0173 (1175/68008). AF 95% confidence interval is 0.0165. There are 22 homozygotes in gnomad4. There are 981 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 22 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MSH2NM_000251.3 linkc.965G>A p.Gly322Asp missense_variant Exon 6 of 16 ENST00000233146.7 NP_000242.1 P43246-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MSH2ENST00000233146.7 linkc.965G>A p.Gly322Asp missense_variant Exon 6 of 16 1 NM_000251.3 ENSP00000233146.2 P43246-1

Frequencies

GnomAD3 genomes
AF:
0.0124
AC:
1889
AN:
152070
Hom.:
22
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00229
Gnomad AMI
AF:
0.0241
Gnomad AMR
AF:
0.00787
Gnomad ASJ
AF:
0.0196
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00769
Gnomad FIN
AF:
0.0319
Gnomad MID
AF:
0.0127
Gnomad NFE
AF:
0.0173
Gnomad OTH
AF:
0.0134
GnomAD3 exomes
AF:
0.0134
AC:
3375
AN:
251428
Hom.:
48
AF XY:
0.0134
AC XY:
1817
AN XY:
135886
show subpopulations
Gnomad AFR exome
AF:
0.00209
Gnomad AMR exome
AF:
0.00598
Gnomad ASJ exome
AF:
0.0220
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00692
Gnomad FIN exome
AF:
0.0310
Gnomad NFE exome
AF:
0.0171
Gnomad OTH exome
AF:
0.0145
GnomAD4 exome
AF:
0.0147
AC:
21504
AN:
1459830
Hom.:
218
Cov.:
29
AF XY:
0.0146
AC XY:
10590
AN XY:
726418
show subpopulations
Gnomad4 AFR exome
AF:
0.00203
Gnomad4 AMR exome
AF:
0.00615
Gnomad4 ASJ exome
AF:
0.0219
Gnomad4 EAS exome
AF:
0.0000504
Gnomad4 SAS exome
AF:
0.00664
Gnomad4 FIN exome
AF:
0.0295
Gnomad4 NFE exome
AF:
0.0158
Gnomad4 OTH exome
AF:
0.0135
GnomAD4 genome
AF:
0.0124
AC:
1885
AN:
152188
Hom.:
22
Cov.:
32
AF XY:
0.0132
AC XY:
981
AN XY:
74392
show subpopulations
Gnomad4 AFR
AF:
0.00229
Gnomad4 AMR
AF:
0.00786
Gnomad4 ASJ
AF:
0.0196
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00769
Gnomad4 FIN
AF:
0.0319
Gnomad4 NFE
AF:
0.0173
Gnomad4 OTH
AF:
0.0133
Alfa
AF:
0.0151
Hom.:
42
Bravo
AF:
0.00931
TwinsUK
AF:
0.0148
AC:
55
ALSPAC
AF:
0.0156
AC:
60
ESP6500AA
AF:
0.00363
AC:
16
ESP6500EA
AF:
0.0153
AC:
132
ExAC
AF:
0.0141
AC:
1709
Asia WGS
AF:
0.00318
AC:
11
AN:
3478
EpiCase
AF:
0.0162
EpiControl
AF:
0.0140

ClinVar

Significance: Benign
Submissions summary: Benign:30Other:1
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not specified Benign:8Other:1
-
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
Mayo Clinic Laboratories, Mayo Clinic
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Sep 19, 2013
ITMI
Significance: not provided
Review Status: no classification provided
Collection Method: reference population

- -

-
Clinical Genetics, Academic Medical Center
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Sep 27, 2013
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Mar 04, 2025
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Lynch syndrome 1 Benign:6
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jul 24, 2014
Pathway Genomics
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Aug 07, 2015
Genome Diagnostics Laboratory, Amsterdam University Medical Center
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mar 06, 2018
Illumina Laboratory Services, Illumina
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. -

Sep 21, 2015
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jul 28, 2017
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome Benign:6
Dec 01, 2017
True Health Diagnostics
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jan 30, 2020
Sema4, Sema4
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: curation

- -

Jan 01, 2022
Color Diagnostics, LLC DBA Color Health
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Dec 18, 2015
Vantari Genetics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nov 18, 2014
Ambry Genetics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Aug 18, 2022
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C.
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Lynch syndrome Benign:3
Apr 08, 2015
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Sep 05, 2013
International Society for Gastrointestinal Hereditary Tumours (InSiGHT)
Significance: Benign
Review Status: reviewed by expert panel
Collection Method: research

MAF >1% & Multifactorial likelihood analysis posterior probability <0.001 -

Nov 30, 2015
Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:3
Jul 13, 2012
Biesecker Lab/Clinical Genomics Section, National Institutes of Health
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: research

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

Nov 02, 2023
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Carcinoma of colon Benign:1
-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

The p.Gly322Asp variant has been identified in 78 out of 3532 proband chromosomes (frequency 0.022) in individuals with endometrial and colorectal cancer phenotypes, however it is also found in 69 out of 2790 control chromosomes (frequency 0.025), increasing the likelihood that this is a benign variant (Barneston 2008, Christensen 2008, Aceto 2009, Hampel 2006, Kurzawski 2006, Raptis 2005, Valentin 2011, Pastrello 2011, Sven Arnold_2009). It is listed in dbSNP database (ID#: rs4987188) with an average heterozygosity of 0.019+/-0.096 in various human populations, further suggesting the benign nature of this variant. The p.Gly322 is highly conserved in mammals and other species, however in silico computational analysis (Sift, PolyPhen and AlignGVGD) do not suggest an impact on the protein function, therefore increasing the likelihood of this variant to be benign. Although functional impact for the yeast homolog (yMSH2–G317D) have been suggeested by earlier yeast assays (Drotschmann 1999; Ellison 2001), recent studies did not implicate any functional impact associated with the p.Gly322Asp variant (Wielders 2011, Kansikas 2011, Ollila 2008). In summary, based on the above information this variant is classified as Benign. -

Hereditary nonpolyposis colorectal neoplasms Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

MSH2 POLYMORPHISM Benign:1
Nov 01, 1998
OMIM
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: literature only

- -

Breast carcinoma Benign:1
Jan 01, 2019
Institute of Human Genetics, University of Leipzig Medical Center
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.32
BayesDel_addAF
Benign
-0.067
T
BayesDel_noAF
Pathogenic
0.15
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.42
T;.;.;.
Eigen
Uncertain
0.34
Eigen_PC
Uncertain
0.44
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Uncertain
0.92
D;D;D;D
MetaRNN
Benign
0.0091
T;T;T;T
MetaSVM
Uncertain
0.093
D
MutationAssessor
Uncertain
2.2
M;.;.;.
PrimateAI
Uncertain
0.56
T
PROVEAN
Benign
-2.0
N;N;.;N
REVEL
Uncertain
0.56
Sift
Benign
0.13
T;T;.;T
Sift4G
Benign
0.25
T;T;.;T
Polyphen
0.43
B;.;.;P
Vest4
0.18
MPC
0.0063
ClinPred
0.016
T
GERP RS
5.6
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Varity_R
0.26
gMVP
0.34

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs4987188; hg19: chr2-47643457; COSMIC: COSV51880340; API